With their deal for respiratory diseases already having reached Phase II trials, Theravance Inc. and GlaxoSmithKline plc said they are broadening their relationship to the tune of $129 million, of which a "significant" portion involves GSK upping its ownership of Theravance from 6 percent to 19 percent - and GSK could end up with as much as 60 percent in 2007. (BioWorld Today) Read More
